18 F-FDG PET/MRI for Diagnosis and Treatment Efficacy Evaluation of Spinal Sarcoidosis

Clin Nucl Med. 2024 Jan 1;49(1):e28-e30. doi: 10.1097/RLU.0000000000004968. Epub 2023 Nov 30.

Abstract

Spinal cord sarcoidosis (SCS) is an uncommon disease with estimated incidence of 0.4% in patients with systemic sarcoidosis. Spinal cord sarcoidosis typically manifests late in the disease course and significantly contributes to patient morbidity. Therefore, early SCS diagnosis and prompt initiation of therapy are crucial. Herein, we report the case of a 51-year-old man with symptomatic SCS managed by 18 F-FDG PET/MRI, allowing diagnosis and treatment efficacy evaluation of spine involvement. We believe that the increasing clinical availability of hybrid PET/MRI devices will offer new opportunities for optimal management of patients with uncommon severe sarcoidosis localizations, such as nervous system.

Publication types

  • Case Reports

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Radiopharmaceuticals / therapeutic use
  • Sarcoidosis* / diagnostic imaging
  • Treatment Outcome

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals